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Abstract
MyD88 adaptor-like protein (Mal) is a crucial adaptor that acts as a bridge to recruit the MyD88 molecule to activated TLR4
receptors in response to invading pathogens. The specific assembly of the Toll/interleukin-1 receptor (TIR) domains of TLR4,
Mal and MyD88 is responsible for proper signal transduction in the TLR4 signaling pathway. However, the molecular
mechanism for the specificity of these TIR domains remains unclear. Here, we present the crystal structure of the TIR domain
of the human Mal molecule (Mal-TIR) at a resolution of 2.4 A ˚. Unexpectedly, Mal-TIR exhibits an extraordinarily long AB loop,
but no aB helix or BB loop, distinguishing it from other TIR domains. More importantly, the Mal-TIR AB loop is capable of
mediating direct binding to the TIR domains of TLR4 and MyD88 simultaneously. We also found that Mal-TIR can form a
back-to-back dimer that may resemble the dimeric assembly of the entire Mal molecule. Our data demonstrate the bridge
role of the Mal-TIR domain and provide important information about TIR domain specificity.
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Introduction
The Toll-like receptors (TLRs) are an important group of
pattern recognition receptors (PRRs) that play a critical role in
host defense against pathogens throughout the animal kingdom
[1,2]. In response to various extracellular ligands, the ectodomain
of a TLR dimerizes [3,4], leading to the rearrangement of its
cytoplasmic Toll/interleukin-1 receptor (TIR) domains to create a
signaling platform for the recruitment of adaptor proteins. This
rearrangement is followed by the expression of inflammatory and
antimicrobial genes in the initiation of the adaptive immune
response [5]. The specificity of TLR signaling depends on the
action of different TIR domain-containing adaptor proteins
(Figure 1A). Five TIR domain-containing adaptor proteins are
currently known: myeloid differentiation factor 88 (MyD88), the
MyD88 adaptor-like protein (Mal), TIR domain-containing
adaptor-inducing interferon-b (TRIF), the TRIF-related adaptor
molecule (TRAM) and the sterile and HEAT/armadillo (ARM)
motif protein (SARM) [6,7].
Mal, which is also identified as the TIR domain-containing
adaptor protein (TIRAP), is essential for the TLR4 and TLR2
signaling pathways [8,9,10]. Mal acts as a bridge adaptor to recruit
the MyD88 molecule to the activated TLR4 dimer on the plasma
membrane [11]. Mal also contains several functional motifs and
can be post-translationally modified. The N-terminus (residues 15–
35) of the Mal molecule is a PIP2-binding domain required for
membrane anchoring [12]. The C-terminus (residues 80–221) of
Mal, referred to as Mal-TIR, is the TIR domain and is required
for interactions with TLR4, TLR2 and MyD88 [8,9]. Mal
contains a putative TRAF6 binding motif (residues 188–196)
within this TIR domain [13]. An E190A mutation in this motif
results in the inhibition of TLR2- and TLR4-mediated activation
of NF-kB [13]. It has also been shown that Mal can be
phosphorylated by Bruton’s tyrosine kinase (Btk) [14,15] and
cleaved by caspase-1 [16], and that both of these modifications are
necessary for its function.
The initiation of intracellular TLR4 signaling is facilitated by
the complex interactions of multiple TIR domains from TLR4,
Mal and MyD88, but the mechanisms of these interactions are still
controversial. Structures of isolated TIR domains from TLRs 1, 2,
10, IL-1RAPL, MyD88, the NP_177436 protein of Arabidopsis
thaliana (AtTIR), the TIR-like protein from Paracoccus denitrificans
(PdTLP) and the flax resistance protein L6 have been reported
[17,18,19,20,21,22,23], but the structure of the TIR domain
complex is still unknown. Several computational models have been
proposed for the homomeric and heteromeric TIR-TIR interac-
tions [22,24,25]. Based on the crystal structure of TLR10-TIR, a
TLR4-TIR dimer model was proposed, and this model suggested
that the TIR dimer interface contains residues from the BB loop,
the DD loop and the aC helix [25]. However, using a decoy
peptide approach and modeling, another group reported that the
BB loop and the aE helix region mediate TLR4-TIR dimerization
[26]. Recently, the small molecule TAK-242 (resatorvid) was
found to directly bind to residue C747 in the TLR4-TIR domain
and to selectively inhibit TLR4 signaling [27,28]. This inhibitor
does not affect the dimerization of TLR4 [28], but interferes with
the interactions between TLR4 and Mal or TRAM [29]. Based on
sequence homology, the residue C747 is located in the aC helix of
the TIR domain [17].
Previous studies have identified genetic variations in TLRs and
adaptor proteins associated with various infectious diseases. The
most interesting single nucleotide polymorphism (SNP) is S180L in
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some infectious diseases, including bacteremia, invasive pneumo-
coccal disease, malaria and atopic dermatitis [30,31]. In human
experimental endotoxemia, individuals heterozygous for S180L
produced significantly more proinflammatory cytokines in re-
sponse to TLR2 and TLR4 ligands in vivo than those homozygous
for S180L, and this response is related to an increased resistance to
infection [32]. Recently, additional rare non-synonymous variants
in the coding region of Mal have been found, and these variants
include A9P, R13W, S55N, D96N, A100T, E132K, R143Q,
R143W, S180L, R184T, E190D, V197I and X222W (a STOP
codon mutated to a tryptophan codon) [31,33,34,35]. Among
these, D96N, E132K, R143Q and E190D have been reported to
cause a loss of function in Mal [31,33]. The D96N mutation has
also been shown to impair recruitment of MyD88 to the plasma
membrane and to influence the post-translational modification of
Mal [33]. Thus, it appears that SNPs in Mal and other TLR-
related proteins can be regarded as important genetic factors in
disease. The crystal structure of Mal-TIR has been recently
determined at 3.0 A ˚ resolution and suggests that the disease-
related mutants D96N and S180L may be involved in the binding
interface of Mal-TIR with MyD88-TIR [36].
To elucidate the specificity of the TIR domains and the
bridging role of the Mal molecule, we examined the structures of
wild-type Mal-TIR at a resolution of 2.4 A ˚ and two disease-related
Mal-TIR variants, D96N and S180L. Structural analysis com-
bined with biochemical data revealed that Mal-TIR can form a
back-to-back dimer with two unexpected AB loops and bind to
TLR4 and MyD88.
Results
Overall structure of Mal-TIR
The crystal structure of human Mal-TIR (residues 79–221) was
determined at a resolution of 2.4 A ˚ using the single wavelength
anomalous dispersion method. The protein crystals were found to
belong to the space group P43212 and to contain one molecule per
asymmetric unit. The overall structure of Mal-TIR consists of a
central five-stranded parallel sheet (bA-bE) surrounded by four
helices (aA, aC-aE) on both sides (Figure 1B). As predicted, the
overall topology is similar to that of the TIR domains of the
receptors TLR1, TLR2, TLR10 and IL-1 RAPL and the adaptor
MyD88 [17,18,19,22]. Among these receptors, the TIR domain of
MyD88 has the highest sequence identity (23%) to Mal-TIR. A
structural comparison of the TIR domains of Mal and MyD88
yields a root-mean-square deviation (RMSD) value of 2.4 A ˚ for
100 equivalent Ca atoms (Figure 2A). The largest differences are
observed in the region from aAt obC (Figure 2A, B). In
comparison with the TIR domain of MyD88, Mal-TIR has an
unusually long AB loop (residues 109–129) and lacks the aB helix
and the BB loop (Figure 2C). The region containing the aB helix
and the BB loop has previously been recognized to mediate the
interactions between different TIR domains [17,24,37,38,39,40].
These unique features of the Mal molecule may be related to its
Figure 1. Crystal structure of Mal-TIR. (A) Schematic illustration of five TIR-domain-containing adaptors involved in TLR signaling. Mal: MyD88
adaptor-like protein; MyD88: myeloid differentiation factor 88; TRIF: TIR-domain-containing adaptor-inducing interferon-b; TRAM: TRIF-related
adaptor molecule; SARM: sterile and HEAT/armadillo (ARM) motif protein; DD: death domain; ID: intermediate domain; SAM: sterile a-motif. (B)
Cartoon representation of the structure of Mal-TIR. The b-strands are shown in pink, the a-helices in cyan and the connecting loops in salmon. The AB
loop is colored red. The red dotted line represents the region that is not resolved in this structure.
doi:10.1371/journal.pone.0034202.g001
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TLR4 signaling pathways.
The AB loop of Mal-TIR interacts with both TLR4 and
MyD88 simultaneously
To screen the regions of Mal-TIR that potentially mediate
interactions with TLR4 or MyD88, we performed a mutational
analysis of 23 amino acid residues using a NF-kB activation
dependent dual luciferase reporter assay in HEK293T cells. The
selected residues are solvent-exposed and highly conserved across
species (Figure S1). The Mal-TIR mutant P125H was used as the
dominant negative control [9]. Among the 23 mutants, five (Y86A,
D87A, F117A, R121A and Y159A) yielded the most severely (less
than 20%) attenuated luciferase signals (Figure 3A). Another five
mutants (E108A, R115A, E132A, W156A and L165A) exhibited
modestly (greater than 20% and less than 50%) attenuated
luciferase signals. Mutation of Y86A and Y159A resulted in the
failure to phosphorylate the tyrosine of Mal by Bruton’s tyrosine
kinase, which has been found to be necessary for TLR2- and
TLR4-dependent NF-kB activation [14,15]. The other mutants,
R115A, F117A and R121A, are located within the AB loop of
Mal-TIR, which suggests that the AB loop may play an important
role in TLR signaling. To test this hypothesis, we further mutated
each residue within the AB loop to investigate each of their roles in
NF-kB activation. Compared to wild type, 7 of 15 mutants
(R115A, F117A, L118A, R121A, D122A, P125A and I129A)
exhibited attenuated (less than 50%) NF-kB activation (Figure 3B).
Because the NF-kB activation dependent dual luciferase
reporter assay is an indirect method of investigating protein-
protein interactions, we used a GST pull-down assay to map
regions of Mal-TIR that mediate the direct binding of Mal-TIR to
MyD88-TIR or TLR4-TIR. Twenty out of the 23 myc-fused
mutants were successfully expressed and purified from E. coli cells.
In comparison to wild-type Mal-TIR, two mutants (E108A and
F117A) resulted in moderately decreased binding of Mal-TIR to
MyD88-TIR (Figure 3C, E). Unexpectedly, these two mutants also
showed significantly reduced binding to TLR4-TIR compared to
the wild-type protein (Figure 3D, E). The F117A mutation is
located inside the AB loop (Figure 2C), and E108 is located at the
C-terminal end of the aA helix close to the AB loop (Figure 2A).
The mutation of E108 may interfere with the conformation of the
AB loop. Taken together, our results suggest that the AB loop of
Figure 2. Comparison of the structures of Mal-TIR and MyD88-TIR. (A,B) Structural comparison of Mal (cyan) and MyD88 (blue). In Mal-TIR,
the AB loop is colored red. In MyD88-TIR, the AB loop is shown in red and the BB loop in magenta. Residues D87, D96, E108, E132, W156, Y159 and
S180 are shown. (C) Sequence alignment between human Mal-TIR and MyD88-TIR based on structural conservation. Note the differences in the
region from aAt obC. Secondary structural elements of both proteins are shown as cylinders (a-helices) and arrows (b-strands). Highly conserved
residues are highlighted in yellow, and residues that are similar across the group of sequences are boxed in red. Residues D87, D96, E108, F117, E132,
W156, Y159 and S180 are labeled with asterisks.
doi:10.1371/journal.pone.0034202.g002
Crystal Structure of Mal-TIR Domain
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34202Figure 3. Mutational analysis of the Mal-TIR domain. (A) Selective mutants of solvent-exposed residues that are highly conserved across
different species and used in the NF-kB reporter assay. (B) Alanine scanning of each residue of the AB loop (except alanine and glycine) for the NF-kB
reporter assay. Black bars indicate decreased (less than 50%) NF-kB activity. RLU: relative luciferase unit; Luc: firefly luciferase activity; Ren: Renilla
luciferase activity. GST pull-down assay for the MyD88-TIR and Mal-TIR variants (C) and for the TLR4-TIR and Mal-TIR variants (D). MyD88-TIR and TLR4-
TIR were purified as GST fusion proteins. Mal-TIR was double-tagged with His6 and Myc and purified with Ni-NTA. The resulting complexes were
analyzed by SDS-PAGE and Western blotting. (E) Bar graph of Mal-TIR wild type and mutants (E108A and F117A) binding to MyD88-TIR (left) or TLR4-
TIR (right). The error bars indicate the standard error of the mean (n=3 separate experiments). * indicates a P value,0.05, ** indicates a P
value,0.001.
doi:10.1371/journal.pone.0034202.g003
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MyD88. Some mutations of the Mal molecule lead to enhanced
association of Mal with TLR4 or MyD88, which is consistent with
previous results [15].
Dimer packing in the Mal-TIR structure
Several studies using the co-immunoprecipitation and yeast
two-hybrid assays have reported that Mal can form homodimers
through its TIR domains [9,24,30,33,34]. Based on our Mal-TIR
crystal structure, two possible interfaces (green-magenta, referred
to as the symmetric dimer; green-yellow, referred to as the
asymmetric dimer) mediate Mal homodimerization (Figure 4A).
The buried surface area, calculated by AREAIMOL [41], is
700 A ˚ 2 for the symmetric dimer and 500 A ˚ 2 for the asymmetric
dimer. The interactions within the interface of the symmetric
dimer primarily involve residues of the aC9 and aD helices of both
monomers (Figure 4B and Figure S2A). Specifically, E190 of the
green monomer forms a hydrogen bond with K158 of the magenta
monomer, and P189 and F193 of the green monomer form
stacking interactions with P155 and W156 of the magenta
monomer, respectively. In addition to these interactions, the side
chain of Y159 of the green monomer interacts hydrophobically
with the side chain of M194 of the magenta monomer, and the
side chains of the L162 of both monomers interact hydrophobi-
cally with each other. All of the interactions described are
reciprocal.
Within the interface of the asymmetric dimer (Figure 4C and
Figure S2B), R184 of the yellow monomer forms several hydrogen
bonds with K84, D85 and D87 of the green monomer. W82 of the
green monomer forms hydrophobic contacts with Y187 of the
yellow monomer. The NH1 atom of R192 of the yellow monomer
makes a hydrogen bond with the main chain carbonyl atom of
S221 of the green monomer.
To validate Mal homodimerization, we mutated the residues
within the interfaces of the dimers and performed GST pull-down
experiments. Our results showed that the W156A and Y159A
mutations located within the interface of the symmetric dimer
caused a significant loss of Mal homodimer formation, while
mutants D87A and R192A did not affect homodimer formation
(Figure 4D, E), indicating that the symmetric dimer observed in
the crystal structure is related to the Mal homodimer formed in
solution.
Discussion
Mal-TIR possesses structural features that distinguish it from
other TIR domains. Previous structural studies have shown that
the BB loop region of TIR is important for mediating interactions
between two TIR domains [17,24,37,38,39,40]. However, we
found that the BB loop was absent in Mal-TIR. Instead of a BB
loop, the Mal-TIR structure contains an extraordinarily long AB
loop. Our alanine scanning experiment showed that most of the
amino acid mutations within the AB loop led to impaired NF-kB
activation. This result is consistent with the previous finding that
the P125H mutant within the AB loop failed to immunoprecipitate
with TLR4 [10]. Moreover, the mutation of another residue
(E132) that is close to the AB loop also led to moderately
attenuated NF-kB activation in the present study. Similarly, it has
been reported that the natural variant E132K leads to a loss of
function of Mal [31]. Furthermore, we found that the D87A
mutation, which is located in the first bA strand of Mal-TIR near
the AB loop, caused severely attenuated NF-kB signaling. In
contrast, mutations at sites outside of both the AB loop and the
interface of the symmetric dimer had no obvious impact on NF-kB
activation. Mutations of residues distal to the AB loop also did not
block the direct interactions between Mal-TIR and either MyD88-
TIR or TLR4-TIR. We conclude that the AB loop of Mal-TIR
plays an important role in TLR signaling through interacting with
TLR4 and MyD88 simultaneously.
Recently, several studies have associated natural variants of Mal
with various infectious diseases [30,31,32,42,43,44,45,46]. To
further understand the molecular mechanism underlying these
associations in the Mal-TIR mutants D96N and S180L, we
determined the crystal structures of these mutants. These
structures showed that neither mutation interferes with the overall
structure of the TIR domain (Figure 5A). We also found that the
surface electronic potential map and hydrophobicity of the Mal-
TIR D96N mutant does not obviously differ from that of the wild-
type protein (Figure 5B, C). Our observations are inconsistent with
the recent conclusion based on an in silico model that the D96N
mutant fails to associate directly with MyD88 because this
mutation affects the distribution of negative charge on the
MyD88 binding site of Mal [36]. Our direct binding assay also
showed that Mal-TIR D96A retains the same binding affinity to
MyD88-TIR and TLR4-TIR as that observed in wild type
(Figure 3), and the D96N mutant is capable of binding with
MyD88-TIR (Figure 5F). Moreover, co-immunoprecipitation
assays and confocal immunofluorescence microscopy have re-
vealed that Mal D96N retains the capacity for physical interaction
with MyD88 [33]. Additionally, the D96E mutant, which retains
the negative charge at that position, results in the complete loss of
NF-kB activation [33]. Thus, we conclude that the loss of function
in Mal D96N is not caused by interference with the interaction
between Mal and MyD88 but instead by another mechanism, such
as altered post-translational modification of Mal [33].
The genetic variant Mal S180L has been reported to provide
protection against various infectious diseases in different ethnic
groups in a number of countries [30,31,32,43,44,46]. In our
crystal structure of Mal S180L, this mutation changed a negatively
charged surface to a positively charged surface (Figure 5D) and a
hydrophilic surface to a hydrophobic surface, thus forming a
continuous hydrophobic surface (Figure 5E). This hydrophobic
patch may play a role in interactions of other binding partners
because the S180L mutant is capable of binding normally with
MyD88-TIR and TLR4-TIR (Figure 5F).
Valkov et al. reported a similar crystal structure of the TIR
domain of human Mal (accession number: 2Y92). The overall fold
of Valkov’s structure is highly similar to ours with a RMSD value
of 0.5 A ˚ for 121 Ca atoms (Figure S3). There are minor structural
differences in the regions of some of the loops, which may be
caused by different crystallization conditions and the resolution of
the respective structures. The crystals of Valkov et al. were
obtained in a solution containing 10–12% PEG 10,000, 5% PEG
3,350, 0.2 M NaCl, 0.1 M Tris-HCl (pH 7.3), and 20 mM DTT
and diffracted to 3.0 A ˚ resolution, while the crystals for this study
were grown in n-cyclohexyl-2-aminoethanesulfonic acid (CHES)
(pH 9.5), 150–300 mM NaCl, 10–20% glycerol and 10 mM DTT
and diffracted to 2.4 A ˚ resolution. Both structures of Mal-TIR
identified the unusually long AB loop instead of the helix aB and
BB loops in other known TIR domains and included two disulfide
bonds (residues C89–C134 and C142–C174) and an additional
DTT molecule that linked two cysteine residues, Cys91 and
Cys157. In this study, we found that Mal interacts with TLR4
using the AB loop by GST pull-down assay, which was in
agreement with the docking model of the TLR4-TIR and Mal-
TIR complex provided by Valkov et al. [36].
However, Valkov et al. proposed that Mal-TIR binds to
MyD88-TIR through an interface containing residues D96, L165
Crystal Structure of Mal-TIR Domain
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show that the D96N and L165A mutants caused significant loss of
the binding of Mal-TIR and MyD88-TIR [36]. However, we
performed GST pull-down assays and found that the AB loop
mediated the direct binding of Mal-TIR with MyD88-TIR. We
also showed that D96N and L165A can bind normally to MyD88-
TIR.
Our crystal structure revealed two possible Mal-TIR dimers.
The symmetric dimer is compatible with the biochemical data and
most likely representative of the Mal dimer in solution. In this
dimer, the AB loops of the two molecules are oriented in opposite
directions, facilitating direct interaction with TLR4 and MyD88.
Using a NF-kB activation report assay, we found that mutations of
two residues (W156 and Y159) within the interface of the
symmetric dimer yielded clearly attenuated NF-kB activation
and a significant loss of Mal homodimerization (Figure 4D, E).
However, the Y159F mutation, but not the Y159A mutation,
apparently maintains the hydrophobic interaction with M194
(Figure 4B) and may thus maintain wild-type function. Indeed, the
Y159F mutant exhibits levels of NF-kB activation comparable to
wild type when Mal is overexpressed in HEK293T cells [14].
Thus, we speculate that the full-length Mal molecule forms back-
Figure 4. Dimeric packing of Mal-TIR. (A) Ribbon representation of two possible interfaces related by crystallographic packing. Chemical
drawing of the key residues involved in the interactions within the interface of the symmetric dimer (B) and the interface of the asymmetric dimer (C).
Hydrogen bonds are shown as dotted red lines and hydrophobic interactions as dotted gray arcs. (D) GST pull-down assay for the homodimerization
of Mal-TIR. Wild type Mal-TIR was purified as a GST fusion protein. Double-tagged (His6 and Myc) Mal-TIR wild type and mutants were purified with Ni-
NTA. The resulting complexes were analyzed by SDS-PAGE and Western blotting. (E) Bar graph of Mal-TIR homodimerization. The error bars indicate
the standard error of the mean (n=3 separate experiments). ** indicates a P value,0.001.
doi:10.1371/journal.pone.0034202.g004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34202Figure 5. Biochemical characteristics of wild-type and mutant Mal-TIR domains. (A) Structural comparison between wild-type and mutant
Mal-TIR domains. Crystal structures of the wild-type (cyan), D96N (magenta) and S180L (yellow) mutants of the Mal-TIR domain are shown. The
residues Asp96 and Ser180 in the wild type as well as Asn96 in D96N and Leu180 in S180L are labeled. Nitrogen and oxygen atoms in the side chains
are colored blue and red, respectively. (B,D) Electrostatic surfaces of wild type and the D96N mutant or the S180L mutant. Surfaces are colored by
electrostatic potential ranging from red (210 kbT/ec) to blue (+10 kbT/ec), where kb is the Boltzmann constant, T is temperature and ec is the electron
charge. The electrostatic potentials were calculated by solving the Poisson-Boltzmann equation with APBS plugin of PyMol program (DeLano
Crystal Structure of Mal-TIR Domain
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34202to-back dimers similar to the symmetric dimer shown herein, and
that the two AB loops on these Mal-TIR dimers interact with
TLR4 and MyD88 simultaneously. Other mutants outside of the
AB loops could also be defective in signaling, although they bind to
TLR4 and MyD88 normally, which could be caused by other
factors such as post-translational modification, mislocalization, etc.
Further examination of structural complexes of hetero-TIR or
homo-TIR domains will provide detailed information about the
specific assembly of TIR domain complexes. Nevertheless, the
data presented here provide important information for under-
standing the specificity of TIR domain assembly and the
molecular basis of the bridging role of Mal in connecting TLR4
and MyD88.
Materials and Methods
Protein Expression and Purification
The gene-encoding residues 79–221 of human Mal protein
(UniProtKB P58753) were cloned into a modified pET-32a
(Novagen) vector in which the thrombin site and the S tag were
replaced by the PreScission site (LEVLFQGP) and transformed
into Escherichia coli BL21 (DE3) codon plus cells. The resulting cells
were then grown in LB medium with 50 mg/L ampicillin at 25uC
to A600=0.6, induced by adding isopropyl-1-thiogalactopyrano-
side (IPTG) to a final concentration of 200 mM and harvested after
overnight. The cells were lysed in T20N300P0.1I20 buffer (20 mM
Tris-HCl, pH 8.6, 0.1 mM phenylmethylsulfonyl fluoride (PMSF),
300 mM NaCl, 20 mM imidazole) using lysozyme (0.1 mg/ml)
and sonication. After centrifugation at 20,000 g for 60 min, the
supernatant was loaded onto Ni-NTA affinity resin (Qiagen),
washed with T20N300P0.1I20 buffer and eluted with the same buffer
with 300 mM imidazole. The eluted His6-tagged protein was
digested by PreScission protease at 4uC overnight. Subsequently,
the TIR domain was loaded for anion-exchange chromatography
(HiTrap Q FF; GE Healthcare) in buffer A T20N30D1E1 (20 mM
Tris-HCl, pH 8.6, 30 mM NaCl, 1 mM DTT, 1 mM EDTA),
then eluted with gradient buffer B T20N1000D1E1 (20 mM Tris-
HCl, pH 8.6, 1000 mM NaCl, 1 mM DTT, 1 mM EDTA) from
3% to 50%. The resulting sample contained protein in a buffer of
20 mM Tris-HCl, pH 8.6, 200 mM NaCl, 1 mM EDTA and
1 mM DTT. The D96N and S180L mutants were produced using
standard PCR-based site-directed mutagenesis and were se-
quenced to confirm the mutations. The D96N and S180L mutants
were expressed and purified following the same protocol used for
the wild-type proteins. The selenomethionine-labeled wild-type
Mal-TIR was expressed by methionine auxotroph E. coli B834
cells in LeMaster media and was purified following the same
protocol used for the wild-type proteins.
For the GST pull-down assay, DNA fragments encoding the
Myc epitope tag (EEQKLISEEDL) were inserted into a pET32a
(Novagen) vector to replace the nucleotides encoding the S-tag,
thioredoxin, and the thrombin-cleavable segment. The wild-type
Mal-TIR was then cloned into this modified pET32a. This
plasmid was used for generating 22 Mal-TIR alanine substitution
variations (Y86A, D87A, E94A, D96A, D102A, Y106A, E108A,
R115A, F117A, R121A, E132A, D154A, W156A, Y159A,
Q163A, L165A, S183A, E190A, R192A, Y196A, D96N and
S180L). All of these point mutations were created using standard
PCR-based site-directed mutagenesis and confirmed by DNA
sequencing. The TIR domains of the Myc-tagged wild-type and
mutant Mal were purified as His6-fusion proteins using a Ni-NTA
column. The Myc-tagged proteins were then transferred to
T20N200D1E1 buffer (20 mM Tris-HCl, pH 8.6, 200 mM NaCl,
1 mM DTT, 1 mM EDTA) using a HiPrep 26/10 Desalting
column (GE Healthcare).
Using PCR, the TIR domains of human Mal (79–221), MyD88
(148–296) and TLR4 (670–839) were amplified from plasmids
containing full-length human MyD88 and TLR4, respectively, in
the BamHI and XhoI sites of pGEX-6P-1 (GE Healthcare). The
proteins were purified on a glutathione Sepharose 4B column (GE
Healthcare) and eluted with elution buffer (50 mM Tris-HCl at
pH 8.0, 10 mM glutathione). The eluted GST-MyD88-TIR was
transferred to T20K100D1E1 buffer (20 mM Tris-HCl pH 7.0,
100 mM KCl, 1 mM DTT, 1 mM EDTA) using a HiPrep 26/10
desalting column (GE Healthcare). The expression and purifica-
tion of GST-TLR4-TIR and GST-Mal-TIR followed the same
protocol as used for GST-MyD88-TIR, with the exception that
the final solution contained protein in a buffer of 20 mM Tri-HCl,
pH 8.0 for GST-TLR4-TIR, and 20 mM Tris-HCl, pH 8.6 for
GST-Mal-TIR.
Crystallization and Data Collection
Crystals of wild-type and Se-Met-substituted Mal-TIR were
grown at room temperature with a protein concentration of
15 mg/ml. These crystals were grown for over 2 weeks using the
hanging drop vapor diffusion method equilibrated against a
reservoir solution of 100 mM CHES, pH 9.5, 150–300 mM
NaCl, 10–20% glycerol and 10 mM DTT. The TIR domains of
the D96N and S180L mutants were crystallized at 20uC for 1
month using the hanging drop vapor diffusion method with a
protein concentration of 15 mg/ml and a reservoir solution
containing 100 mM Tris-HCl, pH 8.0, 200–300 mM NaCl, 12–
15% glycerol and 10 mM DTT. All of the crystals were frozen in a
cryoprotectant consisting of the reservoir solution supplemented
with 40% glycerol.
All data were collected at the Shanghai Synchrotron Radiation
Facility (SSRF). Four types of crystals belong to the space group
P43212. The wild-type Mal-TIR crystals diffracted to 2.4 A ˚ with
unit cell dimensions of a=b=87.51 A ˚ and c=81.68 A ˚. The Se-
Met-substituted crystals diffracted to 2.9 A ˚ with unit cell
dimensions of a=b=87.92 A ˚ and c=82.81 A ˚. The crystals of
D96N diffracted to 2.75 A ˚ with unit cell dimensions of
a=b=86.92 A ˚ and c=81.16 A ˚. The crystals of S180L diffracted
to 3.1 A ˚ with unit cell dimensions of a=b=87.17 A ˚ and
c=80.98 A ˚. All of the datasets were processed and scaled using
the HKL2000 software package [47].
Structure Determination and Refinement
For the wild-type Mal-TIR, the program HKL2MAP [48]
yielded three Se sites in one asymmetric unit. The initial SAD
phases were calculated using PHENIX software [49]. The residues
were first built automatically by the PHENIX program package
and then manually using the COOT program [50] based on 2Fobs
– Fcalc and Fobs – Fcalc difference Fourier maps. The structural
model was refined using the CNS program [51] and the PHENIX
program [49]. The final structure had an Rcryst value of 24.8% and
an Rfree value of 26.2%.
Scientific LLC). (C,E) The molecular surfaces of wild-type (left) and the D96N mutant (right) or the S180L mutant of the Mal-TIR domains. Carbon,
nitrogen, oxygen and sulfur atoms are colored yellow, blue, red and orange, respectively. (F) GST pull-down assay for the interaction of wild-type Mal-
TIR and mutants with TLR4-TIR and MyD88-TIR.
doi:10.1371/journal.pone.0034202.g005
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were determined by the program PHASER [52] using the wild-
type structure as a template. The refinement procedures were
similar to those used for the wild type. The final structure of D96N
had an Rcryst value of 24.7% and an Rfree value of 25.8%. The
final structure of S180L had an Rcryst value of 22.7% and an Rfree
value of 25.4%. Detailed data collection and refinement statistics
are summarized in Table 1.
GST Pull-Down Assay
The GST fusion proteins (GST-MyD88-TIR, GST-TLR4-TIR
and GST-Mal-TIR) and the Myc fusion proteins (Myc-Mal-TIR
wild type and mutants) were each mixed with 30 ml glutathione
Sepharose 4B beads (GE Healthcare) and incubated for binding at
4uC with rocking for 3 hours. The complexes were then washed
four times with wash buffer (20 mM potassium phosphate buffer,
pH 6.4, 50 mM KCl, 0.1 mM EDTA, 10 mM DTT, 0.5 mM
PMSF and 0.5% Triton X-100). The bound proteins were boiled
in SDS sample loading buffer, separated by SDS-PAGE (15%
polyacrylamide) and analyzed using immunoblotting with anti-
Myc antibodies (Sigma).
Luciferase Reporter Assay
The full-length human Mal was used for the NF-kB luciferase
reporter assay. A cDNA encoding the full-length Mal (amino acid
residues 2–221) was cloned into a pCMV-Myc vector. Thirty-five
alanine substitution point mutation variants (Y86A, D87A, E94A,
D96A, L97A, D102A, Y106A, E108A, S110A, T111A, S113A,
L114A, R115A, C116A, F117A, L118A, Q119A, L120A, R121A,
D122A, T124A, P125A, I129A, E132A, D154A, W156A, K158A,
Y159A, Q163A, L165A, S183A, Y187A, E190A, R192A and
Y196A) along with a P125H mutant used as a negative control
were generated using standard PCR-based mutagenesis and
confirmed by DNA sequencing. HEK293T cells (SIBS, CAS,
China) were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (Hyclone) and maintained
at 37uC with 5% CO2 humidity. HEK293T cells (20,000 cells/
well) in 96-well plates were transfected with an NF-kB luciferase
reporter (pGL4.32; 100 ng; Promega), Renilla luciferase control
reporter (pRL-TK; 50 ng; Promega) and Mal variants (pCMV-
Myc; 10 ng) using Lipofectamine 2000 (Invitrogen). Following
incubation for 24 hours, luciferase activity was measured using the
Dual-GloH Luciferase Assay System (Promega) according to the
Table 1. Data collection and refinement statistics.
Crystal name Wild-type Se-Met D96N S180L
Space group P43212 P43212 P43212 P43212
Unit cell (A ˚) a=b=87.51 c=81.68 a=b=87.92 c=82.81 a=b=86.92 c=81.16 a=b=87.17 c=80.98
Wavelength (A ˚) 0.9795 0.9792 0.9792 0.9789
Resolution range (A ˚) 50-2.4 (2.49-2.40)
a 50-2.9 (3.0-2.9)
a 50-2.75 (2.85-2.75)
a 50-3.1 (3.21-3.10)
a
No. of unique reflections 12,504 7,682 8,535 6,063
Redundancy 13.1(8.2)
a 18.8(16.9)
a 13.8(14.4)
a 13.8(14.3)
a
Rsym (%)
b 5.9(44.0)
a 10.5(72.3)
a 7.8(71.7)
a 10.7(60.5)
a
I/s 41.2(3.2)
a 38.2(3.8)
a 33(4.4)
a 27(5.5)
a
Completeness (%) 96.5(80.0)
a 100(100)
a 99.9(100)
a 99.9(99.8)
a
FOM 0.643
Refinement
Resolution range (A ˚) 50-2.40 50-2.75 50-3.10
Rcrystal (%)
c 24.8 24.7 22.7
Rfree (%)
d 26.2 25.8 25.4
RMSDbond (A ˚) 0.008 0.008 0.009
RMSDangle(u) 1.4 1.2 1.2
Number of
Protein atoms 971 971 973
Ligand atoms 8 8 8
Solvent atoms 11 2 2
Residues in (%)
most favored 92.5 91.5 90.6
additional allowed 6.6 6.6 8.5
Generously allowed 0.9 1.9 0.9
disallowed 0 0 0
Average B factor (A ˚2) of Protein 61.5 69.7 70.1
athe highest resolution shell.
bRsym~
P
j SIT{Ij
       
.P
SIT.
cRcrystal~
P
hkl Fobs{Fcalc jj
 P
hkl Fobs.
dRfree, calculated the same as Rcrystal, but from a test set containing 5% of data excluded from the refinement calculation.
doi:10.1371/journal.pone.0034202.t001
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relative stimulation 6 standard deviation (s.d.) for a minimum of
three separate experiments.
Accession Numbers
Atomic coordinates and structure factors for the reported crystal
structures have been deposited in the Protein Data Bank with
accession code 3UB2 for Mal-TIR, 3UB3 for D96N and 3UB4 for
S180L.
Supporting Information
Figure S1 Functional sites of the Mal-TIR domain. (A)
Sequence alignment of Mal-TIR domains from different species:
human (Homo sapiens, P58753), macaque (Macaca mulatta,
B3Y690), chimpanzee (Pan troglodytes, B3Y685), bonobo (Pan
paniscus, B3Y686), gorilla (Gorilla gorilla, B3Y687), mouse (Mus
musculus, Q99JY1), domestic cow (Bos taurus, Q2LGB6), chicken
(Gallus gallus, Q4U127), tropical clawed frog (Xenopus tropicalis,
Q28GU9) and African clawed frog (Xenopus laevis, Q6DFE1).
Accession numbers from UniProtKB are included in brackets.
Secondary structural elements of human Mal-TIR are shown as
cylinders (a-helices) and arrows (b-strands). Arrows indicate the
residues used in functional assays. (B) Results of the gene reporter
assays of NF-kB signaling presented on the crystal structure of the
Mal-TIR. The results of the NF-kB activation assays are mapped
onto the molecular surface of the Mal-TIR domain. Residues Y86,
D87, E108 and E132 are located near the AB loop. Based on the
luciferase assay, the residues shown to be significant (less than
20%) for Mal function deficiency are shown in red, moderately
significant (greater than 20%, less than 50%) for Mal function
deficiency in sky blue, and non-significant (greater than 50%) for
Mal function deficiency in brown.
(TIF)
Figure S2 Stereo view of the detailed interaction within
interfaces of the symmetric dimer (A) and the asym-
metric dimer (B). Oxygen and nitrogen atoms are colored red
and blue, respectively. Hydrogen bonds are shown as red dotted
lines.
(TIF)
Figure S3 Stereo view of the superimposed structures of
Mal-TIR. Our present Mal-TIR structure is colored cyan and
Valkov’s Mal-TIR structure (PDB code 2Y92) is colored gray.
(TIF)
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